表紙
市場調査レポート

Advenchen Laboratories, LLC - 製品パイプラインレビュー

Advenchen Laboratories, LLC - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 226240
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Advenchen Laboratories, LLC - 製品パイプラインレビュー Advenchen Laboratories, LLC - Product Pipeline Review - 2015
出版日: 2015年03月26日 ページ情報: 英文 39 Pages
概要

Advenchen Laboratories, LLC は、小分子癌治療薬の研究開発に取り組む製薬会社で、タンパク質チロシンキナーゼイン阻害剤などのような小分子キナーゼ阻害剤を開発し、癌治療に役立てています。

当レポートでは、Advenchen Laboratories, LLCにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Advenchen Laboratories, LLCの基本情報

  • Advenchen Laboratories, LLCの概要
  • 主要情報
  • 企業情報

Advenchen Laboratories, LLC:R&Dの概要

  • 主な治療範囲

Advenchen Laboratories, LLC:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Advenchen Laboratories, LLC:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Advenchen Laboratories, LLC:薬剤プロファイル

  • YN-968D1
  • AL-3818
  • lucitanib
  • AL-6802
  • AL-2846
  • AL-8326

Advenchen Laboratories, LLC:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Advenchen Laboratories, LLC:最近のパイプライン動向

Advenchen Laboratories, LLC:休止中のプロジェクト

Advenchen Laboratories, LLC:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06896CDB

Summary

Global Markets Direct's, 'Advenchen Laboratories, LLC - Product Pipeline Review - 2015', provides an overview of the Advenchen Laboratories, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Advenchen Laboratories, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Advenchen Laboratories, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Advenchen Laboratories, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Advenchen Laboratories, LLC's pipeline products

Reasons to buy

  • Evaluate Advenchen Laboratories, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Advenchen Laboratories, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Advenchen Laboratories, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Advenchen Laboratories, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Advenchen Laboratories, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Advenchen Laboratories, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Advenchen Laboratories, LLC Snapshot
    • Advenchen Laboratories, LLC Overview
    • Key Information
    • Key Facts
  • Advenchen Laboratories, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Advenchen Laboratories, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Advenchen Laboratories, LLC - Pipeline Products Glance
    • Advenchen Laboratories, LLC - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Advenchen Laboratories, LLC - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Advenchen Laboratories, LLC - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Advenchen Laboratories, LLC - Drug Profiles
    • apatinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-3818
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lucitanib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-6802
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-2846
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-8326
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-58203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AL-58805
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Advenchen Laboratories, LLC - Pipeline Analysis
    • Advenchen Laboratories, LLC - Pipeline Products by Target
    • Advenchen Laboratories, LLC - Pipeline Products by Route of Administration
    • Advenchen Laboratories, LLC - Pipeline Products by Molecule Type
    • Advenchen Laboratories, LLC - Pipeline Products by Mechanism of Action
  • Advenchen Laboratories, LLC - Recent Pipeline Updates
  • Advenchen Laboratories, LLC - Dormant Projects
  • Advenchen Laboratories, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Advenchen Laboratories, LLC, Key Information
  • Advenchen Laboratories, LLC, Key Facts
  • Advenchen Laboratories, LLC - Pipeline by Indication, 2015
  • Advenchen Laboratories, LLC - Pipeline by Stage of Development, 2015
  • Advenchen Laboratories, LLC - Monotherapy Products in Pipeline, 2015
  • Advenchen Laboratories, LLC - Phase III, 2015
  • Advenchen Laboratories, LLC - Phase II, 2015
  • Advenchen Laboratories, LLC - Phase I, 2015
  • Advenchen Laboratories, LLC - IND/CTA Filed, 2015
  • Advenchen Laboratories, LLC - Preclinical, 2015
  • Advenchen Laboratories, LLC - Pipeline by Target, 2015
  • Advenchen Laboratories, LLC - Pipeline by Route of Administration, 2015
  • Advenchen Laboratories, LLC - Pipeline by Molecule Type, 2015
  • Advenchen Laboratories, LLC - Pipeline Products by Mechanism of Action, 2015
  • Advenchen Laboratories, LLC - Recent Pipeline Updates, 2015
  • Advenchen Laboratories, LLC - Dormant Developmental Projects,2015

List of Figures

  • Advenchen Laboratories, LLC - Pipeline by Top 10 Indication, 2015
  • Advenchen Laboratories, LLC - Pipeline by Stage of Development, 2015
  • Advenchen Laboratories, LLC - Monotherapy Products in Pipeline, 2015
  • Advenchen Laboratories, LLC - Pipeline by Top 10 Target, 2015
  • Advenchen Laboratories, LLC - Pipeline by Top 10 Route of Administration, 2015
  • Advenchen Laboratories, LLC - Pipeline by Top 10 Molecule Type, 2015
  • Advenchen Laboratories, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top